Latest News and Press Releases

Alan Horsager, Ph.D., President and Chief Executive Officer of Duet Therapeutics, will present on CpG-STAT3 RNA Silencing and Antisense inhibitors Presentations to cover CpG-STAT3siRNA (DUET-01)...

New patent covers compound and composition and methods of use forCpG-STAT3 Antisense inhibitor (CpG-STAT3ASO) New patent positions Scopus BioPharma’s Subsidiary — Duet Therapeutics — to pursue...

Dr. Rossi is a world leader in the development of RNA interference, the Lidow Family Research Endowed Chair and Professor and Chair of the Department of Molecular and Cellular Biology at the Beckman...

NEW YORK, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”), a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with...

Dr. Kortylewski is the Leading Authority on Bi-Functional Oligonucleotide Cancer Therapeutics and a Professor in the Department of Immuno-Oncology at the Beckman Research Institute at City of Hope...

NEW YORK, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”), a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with...

Duet Therapeutics Integrates Immunotherapy Assets of Scopus and Olimmune, Acquired by Scopus in June 2021 Integration Creates Comprehensive, Industry-Leading Portfolio of Bi-Functional...

NEW YORK, July 12, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”), a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with...

Transaction Creates Global Leader in Oligonucleotide Cancer Therapeutics Combined Assets Target Broad Range of Hematological Malignancies and Solid Tumors NEW YORK, June 30, 2021 (GLOBE...

NEW YORK, May 31, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”) today announced that the board of directors has rescheduled the company’s 2021 Annual Meeting of Stockholders (“2021...